

Degeneración macular
Diabetes
Sistema nervioso
Sistema inmune



**Vigilancia
Tecnológica**
4º trimestre 2013

Este Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge del trabajo conjunto entre la Oficina Española de Patentes y Marcas (OEPM) y ASEBIO como miembro de la Plataforma Tecnológica Española de Mercados Biotecnológicos, y se encuadra dentro de una de las actividades de colaboración que la OEPM viene llevando a cabo con las referidas Plataformas para hacer llegar a las empresas, investigadores, y organizaciones que las integran una selección de las patentes más recientemente publicadas en determinados sectores tecnológicos.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecen una información puntual, esquemática y de rápida

lectura sobre una selección de las últimas patentes biotecnológicas publicadas en el mundo relativas a cuatro líneas de investigación concretas: Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular.


También incluyen noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios. Si se desea recibir este Boletín periódicamente basta con cumplimentar el correspondiente formulario de suscripción.

Se puede acceder al listado de solicitudes de patentes analizadas pulsando sobre las imágenes que aparecen a continuación.


Contenido




DEGENERACIÓN
MACULAR



DIABETES



SISTEMA NERVIOSO



SISTEMA INMUNE

Degeneración Macular

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013169614 A1</u> <u>20131115</u>	ALLERGAN INC [US]	Method of treating amd in patients refractory to anti-vegf therapy
<u>WO2013166240 A1</u> <u>20131107</u>	UNIV TEXAS [US]; UNIV TULANE [US]	Micro-rnas involved in macular degeneration
<u>WO2013164290 A2</u> <u>20131107</u>	FUNDACIO HOSPITAL UNI VALL D HEBRON INST DE RECERCA [ES]	Antibodies or fragments thereof for use in the treatment of ocular diseases
<u>WO2013160879 A1</u> <u>20131031</u>	DAIICHI SANKYO CO LTD [JP]	Anti-robo4-antibody
<u>WO2013155512 A2</u> <u>20131017</u>	UNIV JOHNS HOPKINS [US]; SODHI AKRIT [US]; MONTANER SILVIA [US]	Treatment of ischemic retinopathies
<u>WO2013149086 A1</u> <u>20131003</u>	SOMALOGIC INC [US]	Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
<u>WO2013147140 A1</u> <u>20131003</u>	UNIV KYUSHU NAT UNIV CORP [JP]; AQUA THERAPEUTICS CO LTD [JP]	Nucleic acid molecule capable of inhibiting expression of periostin gene, method for inhibiting expression of periostin gene, and use of said nucleic acid molecule

Diabetes

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013181755 A1</u> <u>20131212</u>	DIAMEDICA INC [CA]	Human tissue kallikrein 1 glycosylation isoforms
<u>WO2013178783 A1</u> <u>20131205</u>	ABLYNX NV [BE]	P2x7 receptor antagonists and agonists
<u>WO2013177588 A1</u> <u>20131128</u>	UNIV JOHNS HOPKINS [US]	C1q/tnf-related protein-9 (ctsp9) and use in prevention and treatment of metabolic disorders
<u>WO2013175038 A1</u> <u>20131128</u>	CONSEJO SUPERIOR INVESTIGACION [ES]	Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations
<u>WO2013175015 A1</u> <u>20131128</u>	UNIV GENEVE [CH]	Identification and functional expression of the mitochondrial pyruvate carrier, mpc1
<u>WO2013173512 A2</u> <u>20131121</u>	UNIV FLORIDA [US]	High-transduction-efficiency raav vectors, compositions, and methods of use
<u>WO2013170636 A1</u> <u>20131121</u>	ADDA BIOTECH INC [CN]	Protein and protein conjugate for diabetes treatment, and applications thereof
<u>EP2664622 A2</u> <u>20131120</u>	UNIV CHINA MEDICAL [TW]	Polypeptides, nucleic acid molecule encoding polypeptides, and uses of polypeptides
<u>WO2013170146 A1</u> <u>20131114</u>	UAB RESEARCH FOUNDATION [US]	Methods and compositions for modulating mir-204 activity
<u>WO2013163887 A1</u> <u>20131107</u>	BEIJING ADVACCINE BIOTECHNOLOGY CO LTD [CN]	Pharmaceutical composition for treating and/or preventing type i diabetes and application thereof
<u>WO2013163377 A1</u> <u>20131031</u>	NOVO NORDISK AS [DK]; AMGEN INC [US]	Human cd30 ligand antigen binding proteins
<u>WO2013162718 A1</u> <u>20131031</u>	EIN STEIN COLL MED [US]	Insulin secretion stimulated by humanin and analogs thereof

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013160879 A1</u> <u>20131031</u>	DAIICHI SANKYO CO LTD [JP]	Anti-robo4-antibody
<u>WO2013159025 A1</u> <u>20131024</u>	EZOSE SCIENCES INC [US]	Biomarkers for diagnosis of diabetes and monitoring of anti-diabetic therapy
<u>WO2013158868 A1</u> <u>20131024</u>	NOGRA PHARMA LTD [IE]; UNIV MIAMI [US]	Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation
<u>WO2013154983 A1</u> <u>20131017</u>	RODGERS KATHLEEN E [US]; DIZEREGA GERE S [US]; LOUIE STAN [US]; MORDWINKIN NICK [US]	Molecular markers of endothelial dysfunction in gestational diabetes
<u>WO2013154709 A1</u> <u>20131017</u>	DIABETOMICS LLC [US]; NAGALLA SRINIVASA R [US]	Maternal biomarkers for gestational diabetes
<u>WO2013151688 A1</u> <u>20131010</u>	GEORGIA REGENTS UNIVERSITY [US]	Methods and compositions for using insulin-like growth factor binding protein 6 in treating and diagnosing diabetes
<u>WO2013151670 A2</u> <u>20131010</u>	MODERNA THERAPEUTICS [US]	Modified polynucleotides for the production of nuclear proteins
<u>WO2013151627 A1</u> <u>20131010</u>	NGM BIOPHARMACEUTICALS INC [US]; KAPLAN DANIEL DAVID [US]; SABERI MAZIYAR [US]; ZHANG BEILIN [US]	Methods of treating glucose metabolism disorders
<u>WO2013151053 A1</u> <u>20131010</u>	UNIV MIYAZAKI [JP]	Method for examining arteriosclerosis
<u>WO2013149729 A2</u> <u>20131010</u>	GLUCOMETRIX AG [DE]	Proinsulin with enhanced helper sequence
<u>WO2013148966 A1</u> <u>20131003</u>	AMYLIN PHARMACEUTICALS LLC [US]; ASTRAZENECA PHARMACEUTICALS LP [US]; REN STEVEN SHIJUN [US]; JIN LI [US]	Transmucosal delivery of engineered polypeptides
<u>WO2013148871 A1</u> <u>20131003</u>	AMYLIN PHARMACEUTICALS LLC [US]; ASTRAZENECA PHARMACEUTICALS LP [US]; ROTH JONATHAN DAVID [US]; GHOSH SOUMITRA S [US]	Engineered polypeptides
<u>WO2013148689 A1</u> <u>20131003</u>	BROD STALEY A [US]	Neuropeptide y treatment of autoimmune disease
<u>WO2013148685 A1</u> <u>20131003</u>	ABBOTT LAB [US]	Pea protein containing nutritional compositions

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013148158 A1</u> <u>20131003</u>	HARVARD COLLEGE [US]	Laser-actuated therapeutic nanoparticles
<u>WO2013146319 A1</u> <u>20131003</u>	AJINOMOTO KK [JP]	Diabetes-inducible bacterium
<u>WO2013144273 A1</u> <u>20131003</u>	SANOFI SA [FR]	Basal insulin therapy
<u>WO2013140393 A1</u> <u>20130926</u>	YISSUM RES DEV CO [IL]; UNIV BEN GURION [IL]	Peptides derived from the d1 - domain of nkp46
<u>WO2013136585 A1</u> <u>20130919</u>	OMRON HEALTHCARE CO LTD [JP]	Device for assisting treatment of diabetes, method for assisting treatment of diabetes and program for assisting treatment of diabetes
<u>WO2013133393 A1</u> <u>20130912</u>	TOKYO MEDICAL UNIVERSITY [JP]; BONAC CORP [JP]	Single-stranded nucleic acid molecule for inhibiting vegf gene expression
<u>WO2013132090 A1</u> <u>20130912</u>	SPHINGOTEC GMBH [DE]	A method for predicting the risk of a subject for contracting diabetes mellitus and/or metabolic syndrome or for diagnosing metabolic syndrome in a subject
<u>WO2013130592 A2</u> <u>20130906</u>	UNIV WAKE FOREST HEALTH [US]	Compositions and methods of enhancing weight gain
<u>WO2013128453 A1</u> <u>20130906</u>	YEDA RES & DEV [IL]	Regeneration of islet beta cells by hsp60 derived peptides
<u>WO2013128450 A1</u> <u>20130906</u>	YEDA RES & DEV [IL]	Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

Sistema Nervioso

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2013181228 A1 20131205	GEN HOSPITAL CORP [US]	Dna modifying fusion proteins and methods of use thereof
WO2013180214 A1 20131205	UNIV KEIO [JP]	Amyotrophic lateral sclerosis and/or frontotemporal lobar degeneration model mouse
WO2013178783 A1 20131205	ABLYNX NV [BE]	P2x7 receptor antagonists and agonists
WO2013177510 A1 20131128	ABBVIE INC [US]	Neuronal nicotinic receptor agonists for treating schizophrenia in patients with variants of comt gene
WO2013172964 A1 20131121	UNIV IOWA RES FOUND [US]; GEN HOSPITAL CORP [US]; DAVIDSON BEVERLY L [US]; HYMAN BRADLEY T [US]	Methods and compositions for treating amyloid deposits
WO2013171233 A1 20131121	INST BIOLOG DOSWIADCZALNEJ IM MARCELEGO NENCKIEGO POLSKA AKADEMIA NAUK [PL]	Use of cacybp/sip in the treatment and diagnosis of alzheimer's disease
EP2664923 A2 20131120	FOND ITALIANA SCLEROSI MULTIPLA FISM ONLUS [IT]; BERTOLOTTO ANTONIO [IT]	Biomarkers for central nervous system diseases
WO2013168174 A1 20131114	UNIV RAMOT [IL]	Apoe4 antibodies for treatment of neurodegenerative conditions
WO2013167681 A1 20131114	UNIV GOETTINGEN GEORG AUGUST [DE]	Conformational-specific antibodies against alphabeta oligomers
WO2013164792 A1 20131107	ISTITUTO ZOOPROFILATTICO SPERIMENTALE DEL PIEMONTE LIGURIA E VALLE D AOSTA [IT]; AVANTEA S R L [IT]	Novel transgenic animal model of amyotrophic lateral sclerosis
WO2013164763 A2 20131107	INNOVATIVE HEALTH DIAGNOSTICS [FR]; CENTRE NAT RECH SCIENT [FR]	A biological complex specific for alzheimer's disease detection in vitro and use thereof
WO2013164354 A1 20131107	AFFIRIS AG [AT]	Composition
EP2659897 A1 20131106	UNIV MARBURG PHILIPPS [DE]	Stem cell derived composition for the treatment of acute injury and degenerative diseases
WO2013160865 A1 20131031	TOLERANZIA AB [SE]; LYCKE NILS [SE]	Immunotolerizing fusion proteins for treatment of multiple sclerosis

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2013160676 A1 20131031	ISIS INNOVATION [GB]	Antibodies against cd106 (vcam-1)
WO2013160176 A1 20131031	SIEMENS AG [DE]; SIEMENS HEALTHCARE DIAGNOSTICS [DE]	Diagnostic mirna profiles in multiple sclerosis
WO2013153179 A1 20131017	LIPOXEN TECHNOLOGIES LTD [GB]	Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis
WO2013153155 A2 20131017	MYCKO MARCIN [PL]; SELMAJ KRZYSZTOF [PL]	The use of mirna particles and mirna antagomir for diagnostics, prevention and treatment of multiple sclerosis
WO2013151762 A1 20131010	AC IMMUNE SA [CH]; UNIV LEUVEN KATH [BE]; GENENTECH INC [US]	Humanized tau antibody
WO2013151729 A1 20131010	UNIV BOSTON [US]	Compositions, methods and assays comprising amylin or amylin analogs for abeta-peptide mediated disorders
WO2013149384 A1 20131010	NIPPON SUISAN KAISHA LTD [JP]; HAN LI [JP]; TSUJI TOMOKO [JP]; LI PENGTAO [CN]; WANG JUN [CN]; LEI HONGTAO [CN]	Brain atrophy prevention agent
WO2013148689 A1 20131003	BROD STALEY A [US]	Neuropeptide y treatment of autoimmune disease
WO2013148283 A1 20131003	ISIS PHARMACEUTICALS INC [US]	Compositions and methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
WO2013148158 A1 20131003	HARVARD COLLEGE [US]	Laser-actuated therapeutic nanoparticles
WO2013144957 A1 20131003	YEDA RES & DEV [IL]; NEUROQUEST LTD [IL]	Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression
WO2013142186 A1 20130926	DANA FARBER CANCER INST INC [US]; GEN HOSPITAL CORP [US]	Isolation and use of human lymphoid organ-derived suppressive stromal cells
WO2013142119 A1 20130926	TUFTS COLLEGE [US]	Silk reservoirs for drug delivery
WO2013140927 A1 20130926	UNIV KYOTO [JP]	Method for screening therapeutic and/or prophylactic agents for alzheimer's disease
WO2013138512 A1 20130919	JANSSEN ALZHEIMER IMMUNOTHERAP [IE]; KIDD DANIEL [US]; STREFFER JOHANNES ROLF [BE]	Oligomeric abeta in the diagnosis, prognosis, and monitoring of alzheimer's disease

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013138244 A2</u> <u>20130919</u>	MEDIMMUNE LLC [US]	Treatment of multiple sclerosis with anti-cd19 antibody
<u>WO2013134636 A1</u> <u>20130912</u>	PURDUE RESEARCH FOUNDATION [US]; MCMASTERS JAMES [US]	Compositions and methods for delivery of kinase inhibiting peptides
<u>WO2013132025 A1</u> <u>20130912</u>	FEBIT HOLDING GMBH [DE]	Mirna based treatment monitoring in multiple sclerosis
<u>WO2013130824 A1</u> <u>20130906</u>	SANGAMO BIOSCIENCES INC [US]	Methods and compositions for treating huntington's disease
<u>WO2013127766 A1</u> <u>20130906</u>	BAYER CROPSCIENCE NV [BE]; BAYER CROPSCIENCE AG [DE]	Als inhibitor herbicide tolerant b. Napus mutants

Sistema Inmune

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013179672 A1</u> <u>20131205</u>	TAKEDA PHARMACEUTICAL [JP]	Method for assessing endometriosis
<u>WO2013178844 A1</u> <u>20131205</u>	UNIV OVIEDO [ES]	Specific aptamers against gluten and associated method for detecting gluten
<u>WO2013178783 A1</u> <u>20131205</u>	ABLIX NV [BE]	P2x7 receptor antagonists and agonists
<u>WO2013177101 A2</u> <u>20131128</u>	SQUIBB BRISTOL MYERS CO [US]	Bispecific antibodies and methods of using the same
<u>WO2013175358 A1</u> <u>20131128</u>	AGRONOMIQUE INST NAT RECH [FR]	Stress-regulated prokaryotic expression cassettes
<u>WO2013175229 A1</u> <u>20131128</u>	MEDICAL RES COUNCIL TECHNOLOGY [GB]	Anti -transglutaminase 2 antibodies
<u>WO2013174264 A1</u> <u>20131128</u>	WUHAN THERASOURCE BIOSCIENCES INC [CN]	Anti-blys antibody
<u>WO2013173255 A2</u> <u>20131121</u>	SORRENTO THERAPEUTICS INC [US]	Antigen binding proteins that bind egfr
<u>WO2013171753 A1</u> <u>20131121</u>	YISSUM RES DEV CO [IL]	Methods of treating and diagnosing diseases using agents that regulate the alternative splicing pathway
<u>WO2013171655 A1</u> <u>20131121</u>	SIGNORILE PIETRO GIULIO [IT]; BALDI ALFONSO [IT]	An in vitro method for diagnosing of endometriosis
<u>WO2013170994 A1</u> <u>20131121</u>	PROTAGEN AG [DE]	Marker sequences for rheumatoid arthritis
<u>WO2013170147 A1</u> <u>20131114</u>	UNIV YALE [US]	Compounds useful for promoting protein degradation and methods using same
<u>WO2013169067 A1</u> <u>20131114</u>	KAEL GEMVAX CO LTD [KR]; KIM SANG JAE [KR]	Composition for preventing or treating rheumatoid arthritis
<u>WO2013168108 A2</u> <u>20131114</u>	NOVARTIS AG [CH]; BROWN ZARIN [GB]; BRADLEY MICHELLE [GB]; CHARLTON STEVEN JOHN [GB]; VAN HEEKE GINO ANSELMUS [GB]; CROMIE KAREN [BE]; DOMBRECHT BRUNO [BE]; STEFFENSEN SOREN [BE]; BAUMEISTER JUDITH [BE]; BOUCHE MARIE-PAULE [BE]; BOUTTON CARLO [BE]; BUYSE MARIE-ANGE [BE]; SNOECK VEERLE [BE]; STAELENS STEPHANIE [BE]	Chemokine receptor binding polypeptides

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013166470 A2</u> <u>20131107</u>	UNIV CALIFORNIA [US]	Uses of cxcl17, a novel chemokine marker of human lung and gastrointestinal disease
<u>WO2013166363 A2</u> <u>20131107</u>	UNIV JOHNS HOPKINS [US]; OLARU ALEXANDRU V [US]; MELTZER STEPHEN J [US]	Methods and compositions useful for diagnosing inflammatory bowel disease-associated neoplasia
<u>WO2013166099 A1</u> <u>20131107</u>	GLAXOSMITHKLINE LLC [US]	Novel antibodies
<u>WO2013165791 A1</u> <u>20131107</u>	BOEHRINGER INGELHEIM INT [DE]; NABOZNY GERALD HENRY [US]	Anti-il-23p19 antibodies
<u>WO2013164440 A1</u> <u>20131107</u>	NOVO NORDISK AS [DK]	Methods related to treatment of inflammatory diseases and disorders
<u>WO2013163377 A1</u> <u>20131031</u>	NOVO NORDISK AS [DK]; AMGEN INC [US]	Human cd30 ligand antigen binding proteins
<u>WO2013163324 A1</u> <u>20131031</u>	BALAGUER XAVIER GRAS [ES]; LUTHER WILLIAM [US]	Method for treating pruritus with cartilage extract
<u>WO2013161814 A1</u> <u>20131031</u>	GENEFONTIER CORP [JP]; UNIV CHIBA NAT UNIV CORP [JP]	Anti-human cd69 antibody, and use thereof for medical purposes
<u>WO2013160879 A1</u> <u>20131031</u>	DAIICHI SANKYO CO LTD [JP]	Anti-robo4-antibody
<u>WO2013158577 A1</u> <u>20131024</u>	LILLY CO ELI [US]	Anti-baff-anti-il-17 bispecific antibodies
<u>WO2013158333 A1</u> <u>20131024</u>	BIO RAD LABORATORIES [US]	Multiplex immunoassay for rheumatoid arthritis and other autoimmune diseases
<u>WO2013156771 A1</u> <u>20131024</u>	THROMBOSIS RES INST [GB]	Anti-atherogenic peptides
<u>WO2013156156 A1</u> <u>20131024</u>	AESKU DIAGNOSTICS GMBH & CO KG [DE]	Method for presymptomatic diagnosis of coeliac disease and gluten sensitivity
<u>WO2013155980 A1</u> <u>20131024</u>	SHANGHAI INST BIOL SCIENCES [CN]	Auto-immune disease-related microrna and use thereof
<u>WO2013153049 A1</u> <u>20131017</u>	INST NAT SANTE RECH MED [FR]; UNIV PARIS SUD XI [FR]	Polypeptides as apelin inhibitors and uses thereof
<u>EP2650310 A1</u> <u>20131016</u>	ROTTAPHARM BIOTECH S R L [IT]	Anti-adamts-5 antibody, derivatives and uses thereof
<u>WO2013152351 A2</u> <u>20131010</u>	UNIV COLUMBIA [US]	Fusion polypeptides and methods of use thereof

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013152114 A1</u> <u>20131010</u>	UNIV MICHIGAN [US]	Biomarker associated with irritable bowel syndrome and crohn's disease
<u>WO2013151669 A1</u> <u>20131010</u>	MODERNA THERAPEUTICS [US]	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
<u>WO2013148736 A1</u> <u>20131003</u>	CODA THERAPEUTICS INC [US]; DUFT BRADFORD J [US]; BECKER DAVID L [GB]	Compositions and treatments based on cadherin modulation
<u>WO2013148350 A2</u> <u>20131003</u>	SANOFI SA [FR]; ZHANG MENG [US]	Anti-light antibody therapy for inflammatory bowel disease
<u>WO2013148267 A2</u> <u>20131003</u>	UNIV MICHIGAN [US]; RICHARDSON BRUCE C [US]; HEWAGAMA ANURA [US]; GORELIK GABRIELA [US]	Epigenetics in autoimmunity
<u>WO2013148158 A1</u> <u>20131003</u>	HARVARD COLLEGE [US]	Laser-actuated therapeutic nanoparticles
<u>WO2013148151 A1</u> <u>20131003</u>	UNIV PITTSBURGH [US]	Plasma microribonucleic acids as biomarkers for endometriosis and endometriosis-associated ovarian cancer
<u>WO2013147899 A1</u> <u>20131003</u>	PHARM CJSC CLOSED JOINT STOCK COMPANY R [RU]; LAVROVSKY YAN [US]; XU TING [US]; REPIK ALEXEY [RU]; GUO KANGPING [CN]; SAMSONOV MIKHAIL [RU]; IGNATIEV VASILY [RU]	Osteoprotegerin derived composition and use thereof
<u>EP2644704 A1</u> <u>20131002</u>	PROTAGEN AG [DE]	Marker sequences for rheumatoid arthritis
<u>WO2013142229 A1</u> <u>20130926</u>	HARVARD COLLEGE [US]; CHILDRENS MEDICAL CENTER [US]; MASSACHUSETTS INST TECHNOLOGY [US]	Designing novel peptides for inducing fibronectin matrix assembly
<u>WO2013142186 A1</u> <u>20130926</u>	DANA FARBER CANCER INST INC [US]; GEN HOSPITAL CORP [US]	Isolation and use of human lymphoid organ-derived suppressive stromal cells
<u>WO2013138909 A1</u> <u>20130926</u>	UNIV MANITOBA [CA]	Detection and modulation of rheumatoid arthritis
<u>WO2013138044 A1</u> <u>20130919</u>	MAYO FOUNDATION [US]; AHLQUIST DAVID A [US]; TAYLOR WILLIAM R [US]; YAB TRACY C [US]; KISIEL JOHN B [US]	Methods and materials for noninvasive detection of colorectal neoplasia associated with inflammatory bowel disease
<u>WO2013136059 A2</u> <u>20130919</u>	ISIS INNOVATION [GB]	Biomarker, uses thereof and therapy
<u>WO2013136040 A1</u> <u>20130919</u>	NOVABIOTICS LTD [GB]	Polypeptides and their use

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013135789 A1</u> <u>20130919</u>	UNIV HASSELT [BE]; LEIDS UNI MEDISCH CT [NL]	Means and methods for the determination of the joint destruction progression rate in rheumatoid arthritis patients
<u>WO2013135748 A1</u> <u>20130919</u>	UNIVERSITAETSKLINIKUM HEIDELBERG [DE]	Polypeptides binding to dll4 and uses thereof
<u>WO2013135747 A1</u> <u>20130919</u>	UNIVERSITAETSKLINIKUM HEIDELBERG [DE]	Polypeptides binding to dll4 and uses thereof
<u>WO2013134431 A1</u> <u>20130912</u>	LIFE TECHNOLOGIES CORP [US]; RAMACHANDRAN NIROSHAN [US]; MENG LIHAO [US]; CHEN GENGXIN [US]; BOURDON DAVID [US]; VAN LE SUZY [US]	Biomarkers for systemic lupus erythematosus
<u>WO2013133298 A1</u> <u>20130912</u>	UNIV TOKYO [JP]; SCHOOL CORP AZABU VETERINARY MEDICINE EDUCATIONAL INSTITUTION [JP]; SCHOOL JURIDICAL PERSON KITASATO INST [JP]; UNIV THE RYUKYUS [JP]	Method for detecting inflammatory bowel disease, and method for testing human salivary flora
<u>WO2013132456 A1</u> <u>20130912</u>	ABOCA SOCIETA S P A SOCIETA AGRICOLA [IT]	Prebiotic mixture
<u>WO2013129454 A1</u> <u>20130906</u>	ASTELLAS PHARMA INC [JP]	Novel anti-human il-23 receptor antibody

Noticias

La OEPM en cifras

La publicación de datos y cifras de Propiedad Industrial (PI) que ofrece la Oficina Española de Patentes y Marcas (OEPM) en este nuevo folleto pretende mostrar una visión general de las actividades relacionadas con las distintas modalidades de protección en materia de PI en el año 2012.



El folleto de rápida consulta, nace con vocación de actualizarse anualmente y aporta información sobre patentes, modelos de utilidad, signos distintivos y diseños industriales. Los datos corresponden tanto a solicitudes presentadas como publicadas, permitiendo las tablas y gráficos que se incluyen apreciar la evolución de las distintas modalidades respecto a los dos años anteriores. [Más información](#)

Subvenciones de la OEPM



El 3 de diciembre de 2013 se han publicado las Resoluciones Definitivas de las solicitudes de subvención correspondientes a la convocatoria 2013 de 'Ayudas para el Fomento de las solicitudes de Patentes y Modelos de Utilidad', tanto del programa nacional como del programa internacional.

Estas ayudas comenzaron en el año 2006 para fomentar las solicitudes de patentes en el exterior y, en el año 2010, para patentes y modelos de utilidad en España. En el caso del programa nacional, el presupuesto se ha ido adaptando a las solicitudes presentadas. El programa internacional se ha consolidado en los últimos años con un crecimiento continuado desde su nacimiento. La Oficina Española de Patentes y Marcas (OEPM) realiza esfuerzos para intentar cubrir la demanda de este tipo de ayudas, consciente de la importancia que la internacionalización tiene para las empresas españolas.

[Más información](#)

Curso "Patent Highlights 2014. Update on Patents in Life Sciences". Madrid, 10 de marzo 2014 y Barcelona 11 de marzo de 2014.



Organizado por la Oficina Española de Patentes y Marcas (OEPM) y el Centro de Patentes de la Universidad de Barcelona (UB), este curso proporciona una actualización sobre algunos de los temas más críticos y recientes de las patentes en este sector, complementando así el curso análogo que se ofreció por los mismos profesores en 2012.

Será impartido en inglés por cuatro agentes de patentes europeos especializados en tramitación de patentes del sector químico, farmacéutico y biotecnológico. [Más Información](#)

